Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
7 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Tyrosine phosphorylation of vitreous inflammatory and angiogenic peptides and proteins in diabetic retinopathy.
Invest Ophthalmol Vis Sci. 2009 Mar;50(3):1378-82. doi: 10.1167/iovs.08-2736. Epub 2008 Oct 31.
Invest Ophthalmol Vis Sci. 2009.
PMID: 18978347
Diabetic Retinopathy Is Associated with Decreased Tyrosine Nitrosylation of Vitreous Interleukins IL-1α, IL-1β, and IL-7.
Reverter JL, Nadal J, Ballester J, Ramió-Lluch L, Rivera MM, Fernández-Novell JM, Elizalde J, Abengoechea S, Rodriguez JE.
Reverter JL, et al. Among authors: abengoechea s.
Ophthalmic Res. 2011 Oct;46(4):169-74. doi: 10.1159/000323812. Epub 2011 Mar 29.
Ophthalmic Res. 2011.
PMID: 21447989
Item in Clipboard
Photodynamic therapy in the management of circumscribed choroidal hemangioma.
Elizalde J, Vasquez L, Iyo F, Abengoechea S.
Elizalde J, et al. Among authors: abengoechea s.
Can J Ophthalmol. 2012 Feb;47(1):16-20. doi: 10.1016/j.jcjo.2011.12.008.
Can J Ophthalmol. 2012.
PMID: 22333845
Item in Clipboard
Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials.
Wong TY, Haskova Z, Asik K, Baumal CR, Csaky KG, Eter N, Ives JA, Jaffe GJ, Korobelnik JF, Lin H, Murata T, Ruamviboonsuk P, Schlottmann PG, Seres AI, Silverman D, Sun X, Tang Y, Wells JA, Yoon YH, Wykoff CC; YOSEMITE and RHINE Investigators.
Wong TY, et al.
Ophthalmology. 2023 Dec 28:S0161-6420(23)00933-8. doi: 10.1016/j.ophtha.2023.12.026. Online ahead of print.
Ophthalmology. 2023.
PMID: 38158159
Free article.
Item in Clipboard
Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial.
Khanani AM, Patel SS, Staurenghi G, Tadayoni R, Danzig CJ, Eichenbaum DA, Hsu J, Wykoff CC, Heier JS, Lally DR, Monés J, Nielsen JS, Sheth VS, Kaiser PK, Clark J, Zhu L, Patel H, Tang J, Desai D, Jaffe GJ; GATHER2 trial investigators.
Khanani AM, et al.
Lancet. 2023 Oct 21;402(10411):1449-1458. doi: 10.1016/S0140-6736(23)01583-0. Epub 2023 Sep 8.
Lancet. 2023.
PMID: 37696275
Item in Clipboard
Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial.
Shimura M, Kitano S, Ogata N, Mitamura Y, Oh H, Ochi H, Ohsawa S, Hirakata A; YOSEMITE and RHINE Investigators.
Shimura M, et al.
Jpn J Ophthalmol. 2023 May;67(3):264-279. doi: 10.1007/s10384-023-00979-8. Epub 2023 Mar 10.
Jpn J Ophthalmol. 2023.
PMID: 36897413
Free PMC article.
Clinical Trial.
Item in Clipboard
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, Lin H, Loewenstein A, Mohan S, Pearce IA, Sakamoto T, Schlottmann PG, Silverman D, Sun JK, Wells JA, Willis JR, Tadayoni R; YOSEMITE and RHINE Investigators.
Wykoff CC, et al.
Lancet. 2022 Feb 19;399(10326):741-755. doi: 10.1016/S0140-6736(22)00018-6. Epub 2022 Jan 24.
Lancet. 2022.
PMID: 35085503
Clinical Trial.
Item in Clipboard
Cite
Cite